Latest News and Press Releases

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory

High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of 20.3 monthsLow incidence of immune-related toxicity:...

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

Autolus presents clinical data update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL at ASCO

Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023